These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 26867397)

  • 1. ADVERSE EVENTS POST-DTAP AND DTwP VACCINATION IN THAI CHILDREN.
    Fortuna L; Sirivichayakul C; Watanaveeradej V; Soonthornworasiri N; Sitcharungsi R
    Southeast Asian J Trop Med Public Health; 2015 Jul; 46(4):764-74. PubMed ID: 26867397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of acellular pertussis-tetanus-diphtheria vaccines and whole-cell pertussis-tetanus-diphtheria vaccines in infancy.
    Korkmaz HA; Aydin A; Unal B
    Paediatr Int Child Health; 2014 Aug; 34(3):198-202. PubMed ID: 24621240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children.
    Pichichero ME; Edwards KM; Anderson EL; Rennels MB; Englund JA; Yerg DE; Blackwelder WC; Jansen DL; Meade BD
    Pediatrics; 2000 Jan; 105(1):e11. PubMed ID: 10617748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children.
    Pichichero ME; Deloria MA; Rennels MB; Anderson EL; Edwards KM; Decker MD; Englund JA; Steinhoff MC; Deforest A; Meade BD
    Pediatrics; 1997 Nov; 100(5):772-88. PubMed ID: 9346976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cellular pertussis vaccine (Infanrix-DTPa; SB-3). A review of its immunogenicity, protective efficacy and tolerability in the prevention of Bordetella pertussis infection.
    Patel SS; Wagstaff AJ
    Drugs; 1996 Aug; 52(2):254-75. PubMed ID: 8841742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody response and reactions to completion of a four-dose series with a two- or three-component acellular pertussis vaccine compared to whole cell pertussis vaccine.
    Pichichero ME; Green JL; Francis AB; Marsocci SM; Murphy AM; Buscarino C
    Scand J Infect Dis; 1996; 28(2):159-63. PubMed ID: 8792483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK.
    Marlow R; Kuriyakose S; Mesaros N; Han HH; Tomlinson R; Faust SN; Snape MD; Pollard AJ; Finn A
    Vaccine; 2018 Apr; 36(17):2300-2306. PubMed ID: 29576304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and reactogenicity of two diphtheria-tetanus-whole cell pertussis vaccines in Iranian pre-school children, a randomized controlled trial.
    Zarei S; Jeddi-Tehrani M; Mehdi Akhondi M; Zeraati H; Ferydonfar AA; Nasernia J; Tavangar B; Shokri F
    Hum Vaccin Immunother; 2013 Jun; 9(6):1316-22. PubMed ID: 23442608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized study of immune responses to two Tdap vaccines among adolescents primed with DTaP and comparison with results among adolescents primed with DTwP.
    Decker MD; Greenberg DP; Johnson DR; Pool V
    Vaccine; 2019 Aug; 37(35):5003-5008. PubMed ID: 31301919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acellular pertussis vaccine boosters combined with diphtheria and tetanus toxoid boosters for adolescents: safety and immunogenicity assessment when preceded by different 5-dose DTaP/DTwP schedules.
    Pichichero ME; Casey JR; Francis AB; Marsocci SM; Murphy M; Hoeger W; Cleary C
    Clin Pediatr (Phila); 2006 Sep; 45(7):613-20. PubMed ID: 16928838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diphtheria-tetanus-acellular pertussis vaccine adsorbed (Triacelluvax; DTaP3-CB): a review of its use in the prevention of Bordetella pertussis infection.
    Matheson AJ; Goa KL
    Paediatr Drugs; 2000; 2(2):139-59. PubMed ID: 10937466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of Diphtheria and Tetanus Toxoids and Acellular Pertussis (DTaP) Vaccine in Adults in Japan.
    Ujiie M; Tsuzuki S; Suzuki M; Ota M; Suzuki T; Nomoto H; Yamamoto K; Saito S; Kokaze A; Kinoshita N
    Jpn J Infect Dis; 2021 Sep; 74(5):399-404. PubMed ID: 33518629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
    Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
    Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of acellular pertussis vaccine with whole cell vaccine as a booster in children 15 to 18 months and 4 to 6 years of age.
    Bernstein DI; Smith VE; Schiff GM; Rathfon HM; Boscia JA
    Pediatr Infect Dis J; 1993 Feb; 12(2):131-5. PubMed ID: 8426770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of acellular pertussis vaccines: the Mainz study and other recent studies.
    Weigl JA; Bock HL; Clemens R; Zepp F; Habermehl P; Beutel K; Müschenborn S; Sümenicht G; Schuind A; von König CH; Neiss A; Laukamp S; Kiederle S; Schmitt HJ
    Ann Acad Med Singap; 1997 May; 26(3):320-5. PubMed ID: 9285026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 15- through 20-month-old infants.
    Bernstein HH; Rothstein EP; Reisinger KS; Blatter MM; Arbeter AM; Fontana ME; Jacobs JM; Long SS; Rathfon H; Crayne O
    Pediatrics; 1994 Apr; 93(4):656-9. PubMed ID: 8134224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine.
    Langley JM; Predy G; Guasparini R; Law B; Diaz-Mitoma F; Whitstitt P; Tapiero B; Dionne M; Tomovici A; Mills E; Halperin SA
    Vaccine; 2007 Jan; 25(6):1121-5. PubMed ID: 17045366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: a randomized, controlled study in infants in the Republic of Korea.
    Lee SY; Hwang HS; Kim JH; Kim HH; Lee HS; Chung EH; Park SE; Ma SH; Chang JK; Guitton F; Ortiz E; Kang JH
    Vaccine; 2011 Feb; 29(8):1551-7. PubMed ID: 21215828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minor adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group.
    Schmitt-Grohé S; Stehr K; Cherry JD; Heininger U; Uberall MA; Laussucq S; Eckhardt T
    Dev Biol Stand; 1997; 89():113-8. PubMed ID: 9272341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    MMWR Recomm Rep; 1997 Mar; 46(RR-7):1-25. PubMed ID: 9091780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.